Pathology: mCRC - 2nd line (L2);
| mCRC - 2nd line (L2) | ||||
| IMblaze-370 (A ; all population), 2019 | IMblaze-370 (AC ; all population), 2019 | CO.26 study, 2020 | ||
| durvalumab plus tremelimumab | 1 | T1 | ||
| atezolizumab alone | 1 | T1 | ||
| atezolizumab plus cometinib | 1 | T1 | ||
| BSC | 0 | T0 | ||
| regorafenib | 0 | T0 | T0 | |